InvitaeIR
@InvitaeIR
Followers
83
Following
1
Media
8
Statuses
62
@invitae Investor Relations. Our mission is to bring genetic information into mainstream medical practice to improve the health of billions of people. #reINVent
San Francisco, CA
Joined May 2015
On 5/8, $NVTA presents Q1: 2017 financial results. We encourage shareholders to send questions to ir@invitae.com to be answered during Q&A.
0
0
0
BRCA1/2 data sharing – An in-depth look at the issues:
Two Groups Evaluating #BRCA Variant Discrepancies in Public Database at Odds Over Patient Impact https://t.co/nc1AHwVzvv $MYGN $NVTA
0
0
0
0
2
0
Q3 2016 marks @Invitae's 8th consecutive quarter of solid execution against our four key metrics. https://t.co/d4XWnfHPNk
0
0
0
Advocates partnering for patients @NYSE #HBOCWeek16 @Sharsheret @CancerSupportCm @NOCC_National @RivkinCenter @cancanhealth @FacingOurRisk
0
6
4
$NVTA Q2 2016 earnings transcript: https://t.co/1veUe2344L Webcast & slides: https://t.co/iB7jR7hSbx Announcement:
ir.invitae.com
– Accelerated development of a 20,000-gene medical exome to be available in Q1:2017 – – Nearly tripled volume with more than 12,000 test reports delivered – – Lowered COGS to approximately $500 – –...
0
0
0
Partnering w/ payers to achieve mutually beneficial goal: provide high quality, low cost genetic testing to patients
0
0
1
$NVTA's business model is providing investors with unique opportunity to invest in the future of genomic medicine
ir.invitae.com
– Accelerated development of a 20,000-gene medical exome to be available in Q1:2017 – – Nearly tripled volume with more than 12,000 test reports delivered – – Lowered COGS to approximately $500 – –...
0
1
0
$NVTA executing on key metrics; "leapfrogging" year-end goal to ~20K-gene boosted exome https://t.co/85qgXeylwj
0
0
0
Reimbursement is a key driver in demonstrating $NVTA's operational leverage and efficiency https://t.co/85qgXeylwj
0
0
0
$NVTA believes the reimbursement tide is turning rapidly as payers adopt our low cost platform
ir.invitae.com
– Accelerated development of a 20,000-gene medical exome to be available in Q1:2017 – – Nearly tripled volume with more than 12,000 test reports delivered – – Lowered COGS to approximately $500 – –...
0
0
0
$NVTA saw $1 million improvement quarter over quarter on gross margins and bottom line https://t.co/85qgXeylwj
0
0
0
NVTA Q2 2016 financials, secures contract with national payer, accelerates development of 20K-gene medical exome
0
0
0
$NVTA tweets include forward-looking statements about future events. Actual results could be different https://t.co/85qgXeylwj
#NVTAearnings
ir.invitae.com
– Accelerated development of a 20,000-gene medical exome to be available in Q1:2017 – – Nearly tripled volume with more than 12,000 test reports delivered – – Lowered COGS to approximately $500 – –...
0
0
0
“We are at the beginning of a competitive race to provide high quality, low cost genetic testing to everyone on the planet.” Randy Scott CEO
0
0
0
By combining high quality genetic testing with low cost, $NVTA is bringing genetic analysis into mainstream medicine.
0
0
0
Finally, $NVTA expanded our pediatric and rare disorder test menu with more than 40 test panels comprised of more than 140 genes.
0
0
0
$NVTA also expanded our neuromuscular test panels, comprising nearly 100 carefully curated genes, for 15 major diagnostic indications.
0
0
0
$NVTA made other important expansions, including more comprehensive cancer testing with more than 40 panels comprised of more than 70 genes.
0
0
0